ARS Pharmaceuticals, Inc. - Common Stock (SPRY)

CUSIP: 82835W108

Q3 2024 13F Holders as of 30 Sep 2024

Holder snapshot 7 signals
Share change
+1,343,166
Put/Call ratio
68%
SEC-reported price per share
$14.50
Number of holders
148
Value change
+$31,092,478
Number of buys
103
Open additional details 1 more signal available
Number of sells
34
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
98,457,811

Security key

82835W108

Report period

Q3 2024

Institutions

148

Top holders

10

Ownership snapshot

Top reported holders of SPRY - ARS Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
DEERFIELD MANAGEMENT COMP...
Disclosed value leader
DEERFIELD MANAGEMENT COMP...
Comparable rows
0/15
Latest evidence
30 Jun 2024
13F Highest disclosed value: $94,273,159 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

DEERFIELD MANAGEMENT COMPANY, L.P. has the largest disclosed position value at $94.27M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens DEERFIELD MANAGEMENT COMPANY, L.P.'s linked filing trail.
Disclosed position value Top 5
DEERFIELD MANAGEMENT COMPANY, L.P. $94.27M
RA CAPITAL MANAGEMENT, L.P. $92.43M
ORBIMED ADVISORS LLC $78.64M
BlackRock Finance, Inc. $34.76M
SR ONE CAPITAL MANAGEMENT, LP $34.15M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
DEERFIELD MANAGEMENT COMPANY, L.P.
13F
Company
13F
—
denominator unverified
$94,273,159
11,077,927 shares
— 30 Jun 2024
RA CAPITAL MANAGEMENT, L.P.
13F
Company
13F
—
denominator unverified
$92,426,914
10,860,977 shares
— 30 Jun 2024
ORBIMED ADVISORS LLC
13F
Company
13F
—
denominator unverified
$78,639,948
9,240,887 shares
— 30 Jun 2024
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$34,757,725
4,084,339 shares
— 30 Jun 2024
SR ONE CAPITAL MANAGEMENT, LP
13F
Company
13F
—
denominator unverified
$34,149,805
4,012,903 shares
— 30 Jun 2024
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$27,665,389
3,250,927 shares
— 30 Jun 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
148
Shares
63,765,651
Rows available
148
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2024 vs Q2 2024 Across Filers

Q2 2024 holders
112
Q3 2024 holders
148
Holder diff
36
Investor Q2 2024 Shares Q3 2024 Shares Share Diff Share Chg % Q2 2024 value Q3 2024 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .